Welcome to our dedicated page for Corbus Pharmaceu SEC filings (Ticker: CRBP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Corbus Pharmaceuticals Holdings, Inc. filings document a clinical-stage biotechnology issuer focused on oncology and obesity. The record includes Form 8-K material-event reports for clinical and regulatory disclosures involving CRB-701 and CRB-913, Regulation FD corporate presentations and risk language tied to product development, trial timelines and business strategy.
Proxy and governance filings cover board matters, executive compensation, equity awards, employment agreements and officer or director changes. The filings also provide formal disclosure categories for operating and financial results and the governance framework supporting the company’s drug-development pipeline.
Corbus Pharmaceuticals Holdings, Inc. reports that the last patient has been enrolled and completed the first clinical visit in its CANYON-1 Phase 1b trial of CRB-913 for obesity, keeping the study on track for completion in summer 2026. CANYON-1 is a 16-week, double-blind, placebo-controlled, dose-ranging study in 240 obese, non-diabetic participants at multiple U.S. sites. The trial tests once-daily oral CRB-913 at 20 mg, 40 mg, and 60 mg with dose titration from 20 mg, followed by one month of post-dosing monitoring. Earlier Phase 1a data showed CRB-913-treated obese participants achieved a mean 2.9% placebo-adjusted weight loss by Day 14 at 150 mg/day and the drug was reported as safe and well-tolerated, with a favorable gastrointestinal and neuropsychiatric profile.
Corbus Pharmaceuticals Holdings, Inc. announced broad alignment with the U.S. Food and Drug Administration on the registration path for CRB-701, its Nectin-4–targeting antibody drug conjugate, in second-line head and neck squamous cell carcinoma and cervical cancer. The agreed plans call for single, randomized controlled registrational studies in each indication, comparing CRB-701 to physicians’ choice chemotherapy or chemotherapy/Tivdak, with potential accelerated approval based on objective response rate and potential full approval based on overall survival.
The FDA has granted two Fast Track designations to CRB-701 in head and neck squamous cell carcinoma and cervical cancer. Updated Phase 1/2 monotherapy data will be presented at ASCO 2026, and the company anticipates reporting first-line HNSCC combination data with Keytruda in Q4 2026. Corbus expects to initiate a registrational study in second-line HNSCC in mid-2026. The company also disclosed that Chief Medical Officer Dr. Dominic Smethurst will step down effective June 30, 2026, as it adds new senior leaders for the next development phase.
Corbus Pharmaceuticals Holdings, Inc. is asking stockholders to vote at a virtual annual meeting on May 13, 2026. Proposals include electing six directors, approving an amendment to the 2024 Equity Compensation Plan to raise the share reserve by 3,000,000 shares to 5,000,000 shares, ratifying EisnerAmper LLP as auditor for 2026, and advisory votes on executive pay and how often to hold future say‑on‑pay votes, with the Board recommending an annual frequency. As of March 23, 2026, 17,736,464 shares of common stock were outstanding and entitled to one vote per share. The proxy also details 2025 executive pay, governance practices, board committee composition and activity, and pay‑versus‑performance data showing a 2025 net loss alongside higher cumulative total shareholder return.
Corbus Pharmaceuticals Holdings, Inc. registers an aggregate $300,000,000 shelf to offer common stock, preferred stock, warrants, debt securities, subscription rights and units under a shelf registration statement.
The prospectus states the offerings may be made separately or together in one or more offerings and that aggregate public offering price will not exceed $300,000,000. The document lists that 17,736,464 shares of common stock were issued and outstanding as of March 6, 2026.
Corbus Pharmaceuticals Holdings, Inc. files a registration statement to offer up to $300,000,000 of securities under a shelf prospectus. The shelf permits the company to issue common stock, preferred stock, warrants, debt securities, subscription rights and units from time to time, in one or more offerings.
The prospectus states the aggregate public offering price will not exceed $300,000,000 and that specific terms, listing information and use of proceeds for each issuance will be provided in future prospectus supplements. The prospectus also discloses 17,736,464 shares of common stock issued and outstanding as of close of business on March 6, 2026.
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biotech focused on oncology and obesity, reporting a net loss of $78.5 million in 2025 and cumulative losses of $555.4 million. Cash, cash equivalents and investments were $163.3 million, supporting development but not yet reaching profitability.
The lead oncology asset, CRB-701, a Nectin-4–targeting antibody-drug conjugate, showed encouraging Phase 1/2 activity across head and neck, cervical and urothelial cancers, with notable objective response and disease control rates and a differentiated emerging safety and pharmacokinetic profile versus PADCEV®. The FDA granted fast track designations in relapsed or refractory metastatic cervical cancer and in certain head and neck cancers, and the company plans FDA discussions on registrational study designs in 2026.
In obesity, oral CB1 inverse agonist CRB-913 completed a Phase 1a SAD/MAD trial with no serious adverse events, minimal gastrointestinal effects and a mean 2.9% placebo‑adjusted weight loss by Day 14 in an obese cohort at 150 mg once daily. A 240‑subject Phase 1b CANYON‑1 study began in late 2025. The earlier oncology antibody CRB‑601 has been deprioritized. Corbus increased 2025 research and development spending to $70.1 million and raised additional capital through an at-the-market program and a $70.2 million underwritten equity offering.
Corbus Pharmaceuticals Holdings, Inc. reported a larger net loss as it advanced its oncology and obesity pipeline and strengthened its balance sheet. Net loss was $20.6 million, or $1.25 per share, for Q4 2025, compared with $9.5 million, or $0.78 per share, a year earlier, driven mainly by higher clinical development spending.
For full-year 2025, net loss was $78.5 million versus $40.2 million in 2024, as research and development expenses more than doubled to $70.1 million. The company ended 2025 with $163.3 million in cash, cash equivalents and investments, and stated this is expected to fund operations into 2028.
Corbus highlighted promising clinical signals from its three key programs. CRB-701, a next‑generation Nectin‑4 antibody‑drug conjugate with FDA Fast Track designations in head and neck squamous cell carcinoma and cervical cancer, showed encouraging Phase 1/2 response rates and a favorable emerging safety profile, with additional monotherapy data and a registrational study update planned for mid‑2026.
CRB-913, an oral CB1 inverse agonist for obesity, produced placebo‑adjusted weight loss of 2.9% over 14 days with favorable gastrointestinal and neuropsychiatric assessments, and a 12‑week, 240‑patient Phase 1b study is expected to complete in summer 2026. The company completed a $75 million public offering in Q4 2025, which it says extended its cash runway into 2028 while it focuses on oncology and obesity opportunities.
Corbus Pharmaceuticals Holdings, Inc. Chief Medical Officer Dominic Smethurst reported an open-market sale of 6,097 shares of common stock at a weighted average price of $8.2994 per share. The sale was mandated to cover tax withholding on vesting RSUs and was not a discretionary trade. After this transaction, he directly holds 89,790 shares, including 73,765 unvested RSUs that remain subject to their vesting schedules.